<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542006</url>
  </required_header>
  <id_info>
    <org_study_id>0647-17</org_study_id>
    <nct_id>NCT03542006</nct_id>
  </id_info>
  <brief_title>Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy</brief_title>
  <official_title>Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors
      have been shown to be effective for the treatment of macular edema when administered orally,
      also for central serous chorioretinopathy. However, this treatment carries the risk of severe
      side effects.

      The goal of this study is to examine the efficacy of the topical form of treatment of
      carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous
      chorioretinopathy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in subretinal fluid (microns)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in subretinal fluid as measured by optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ETDRS visual acuity (number of letters)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in visual acuity from baseline to last follow-up in ETDRS letters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central macular thickness (microns)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in central macular thickness in microns from baseline to last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in choroidal thickness (microns)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in choroidal thickness in microns from baseline to last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for fluid resolution (days)</measure>
    <time_frame>6 months</time_frame>
    <description>Time in days from baseline until fluid resolution, as measured on optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with fluid resolution</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients with fluid resolution by last follow-up as seen on optical coherence tomography, out of all study participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment (using NEI-VFQ-25 questionnaires)</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life score as assessed by standard questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Topical brinzolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brinzolamide ophthalmic, given bd for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide Ophthalmic</intervention_name>
    <description>Topical brinzolamide given bd for 3 months</description>
    <arm_group_label>Topical brinzolamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4
             months of follow-up

          -  Optical coherence tomography (OCT) shows foveal subretinal fluid

          -  Fluorescein angiography and indocyanine green confirm the diagnosis

        Exclusion Criteria:

          -  Any other ophthalmic condition that may lead to subretinal fluid

          -  Choroidal neovascularization

          -  Myopia &gt; -6D

          -  Previous treatment for CSC in the past 6 months

          -  Known allergy to fluorescein or indocyanin green

          -  Known allergy for brinzolamide

          -  Pregnancy, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dinah Zur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dinah Zur, MD</last_name>
    <phone>+97236973408</phone>
    <email>dinahzur@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roy Schwartz, MD</last_name>
    <phone>+447392971069</phone>
    <email>royschwartz@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Iglicki Oftalmologia</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <last_name>Matias Iglicki</last_name>
      <phone>+5491148562937</phone>
      <email>matiasiglicki@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Dinah Zur, MD</last_name>
      <phone>+97226973408</phone>
    </contact>
    <contact_backup>
      <last_name>Roy Schwartz, MD</last_name>
      <phone>+447392971069</phone>
      <email>royschwartz@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Michaella Goldstein</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

